Celyad SA (NYSE Euronext Brussels and NYSE Euronext Paris: CYAD), disclose the information required under article 15, § 1 of the Law of 2 May 2007 regarding the disclosure of important shareholdings in listed companies.

Following the exercise of 4,900 warrants of the Company on 2 May 2017, the share capital is increased to 33,130,912.63 EUR and is represented by 9,525,753 shares.

FIGURES – MODIFIED ON 2 MAY 2017 FOLLOWING THE EXERCISE OF WARRANTS

New shares issued following the exercise of Company’s warrants: 4,900.

Company’s share capital: 33,130,912,63 EUR.

Total number of shares with voting rights: 9,525,753.

Total number of voting rights (= denominator): 9,525,753.

STATUTORY THRESHOLDS – UNCHANGED

Statutory thresholds for participation (article 12 of the by-laws): 5%, 10%, 15%, 20% and so by increments of 5%.

CONTACT PERSON FOR REGULATED INFORMATION (FINANCIAL, TRANSPARENCY)

According to Law, any transparency declaration must be sent to our Company by email to the attention of Patrick Jeanmart, Chief Financial Officer (CFO): pjeanmart@celyad.com.

Further questions about the content of this release can be sent to investors@celyad.com.

Download press release(s)

Press release

72.68 Ko

Communiqué de presse

77.40 Ko

About Celyad

Developing breakthrough pioneering therapies for life-threatening diseases.

Celyad is a biopharmaceutical company, specialized in cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis. Our scientific approach is inspired by the natural mechanisms that are used by the body to fight disease.

Read more about Celyad

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Next News

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®